Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumat...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: www.artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

aim97 Oct. 23 at 1:25 PM

$ARTL whats with the reversal i didnt get a chance to DCA at sub 3.20 like i wanted. hopefully quickly up so i can exit.

1 · Reply

Foamius2 Oct. 22 at 4:39 PM

$ARTL Daniel Fart is out of 95% of his position-good riddance

0 · Reply

ttesty Oct. 22 at 1:53 PM

$ENSC is almost $1.80. Keep falling. $ARTL ftw.

0 · Reply

elmono Oct. 21 at 11:49 AM

$ARTL As a result of ongoing discussions with potential partners and the supportive clinical profile of ART27.13 for CACS, Artelo does not envision the need to internally fund a Phase 3 trial and believes a licensing transaction represents the most value-accretive path forward for shareholders. “This morning’s interim results highlight the potential of ART27.13 to become an FDA and internationally approved therapy for cancer anorexia-cachexia syndrome, an underserved, multi-billion-dollar potential market,” said Gregory D. Gorgas, President and CEO of Artelo. “Based on strong interest from multiple pharmaceutical companies, and given the strength of our newly released data, our immediate strategy is to secure a development partner to efficiently advance ART27.13 through registrational trials. We plan to provide further updates as soon as practical.” Soon 2 months and nothing ….,how about that strong interest, you F’Ups. 😂😂🫵

1 · Reply

YolandaMantel1102 Oct. 20 at 4:18 PM

$ARTL evolving in biotech, AITX evolving in automation — the latest update reflects consistent growth and rising recognition.

0 · Reply

StockHounding Oct. 19 at 1:58 AM

$BCG : Bids climbing gradually Yeah, no need to slap here Just keep bid stacking until squeeze Iit's going to explode No borrow, no floater $CDTG manufactured price movement $ARTL ready as F $PNBK next squeeze? $DTSS just hanging out

0 · Reply

MrTicker Oct. 17 at 9:08 PM

$ARTL Oct 17 (Reuters) - Artelo Biosciences Inc(ARTL): * ARTELO BIOSCIENCES INC(ARTL) - ENTERS COOPERATION LETTER AGREEMENT WITH DANIEL S. FARB AND CERTAIN OF HIS AFFILIATES - SEC FILING * ARTELO BIOSCIENCES INC(ARTL) - FARB AGREED WITHDRAWS NOMINATION OF CANDIDATES FOR ELECTION TO BOARD AT 2025 ANNUAL MEETING - SEC FILING * ARTELO BIOSCIENCES INC(ARTL) - FARB AND AFFILIATES AGREE TO STANDSTILL RESTRICTIONS AND VOTING COMMITMENTS - SEC FILING Source text: Further company coverage:

0 · Reply

MrTicker Oct. 17 at 9:08 PM

$ARTL BRIEF-Artelo Biosciences enters cooperation letter agreement with Daniel S. Farb - SEC filing REUTERS 4:06 PM ET 10/17/2025

0 · Reply

MrTicker Oct. 17 at 9:03 PM

$ARTL updated 13D Form SCHEDULE 13D/A ARTELO BIOSCIENCES, INC. Filed by: Farb Daniel Stuart 10K WIZARD 4:02 PM ET 10/17/2025 http://archive.fast-edgar.com/20251017/AF28K622U2223ZZ2222O2ZEPDMTUZ222V272 Filed on: October 17, 2025

0 · Reply

Paraboljoker Oct. 16 at 9:40 PM

$SUGP BIO/Hospital contract 11M🗞️ Worth Entire mcap 400k float, numers dont lie this will blow Sector hot🔥 / / $NCT $XBP $ARTL $ZBIO

0 · Reply

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 24 days ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 25 days ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 25 days ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 26 days ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 7 weeks ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 7 weeks ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 7 weeks ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 7 weeks ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 2 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 2 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 9:15 AM EDT - 2 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 4, 2025, 7:30 AM EDT - 2 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 3 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 9, 2025, 7:50 AM EDT - 3 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 8, 2025, 3:06 PM EDT - 3 months ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 7, 2025, 7:45 AM EDT - 3 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 4 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 4 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 11, 2025, 8:30 AM EDT - 4 months ago

Artelo Biosciences Announces Reverse Stock Split

Jun 5, 2025, 9:00 AM EDT - 5 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 5 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 8:00 AM EDT - 5 months ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 6 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 7 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 8 months ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Feb 14, 2025, 9:00 AM EST - 9 months ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 9 months ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Jan 13, 2025, 9:00 AM EST - 10 months ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Dec 9, 2024, 9:15 AM EST - 11 months ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 3, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

May 29, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 12, 2024, 9:15 AM EDT - 1 year ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Feb 15, 2024, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Jan 23, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Jan 8, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Dec 5, 2023, 8:30 AM EST - 2 years ago

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

aim97 Oct. 23 at 1:25 PM

$ARTL whats with the reversal i didnt get a chance to DCA at sub 3.20 like i wanted. hopefully quickly up so i can exit.

1 · Reply

Foamius2 Oct. 22 at 4:39 PM

$ARTL Daniel Fart is out of 95% of his position-good riddance

0 · Reply

ttesty Oct. 22 at 1:53 PM

$ENSC is almost $1.80. Keep falling. $ARTL ftw.

0 · Reply

elmono Oct. 21 at 11:49 AM

1 · Reply

YolandaMantel1102 Oct. 20 at 4:18 PM

$ARTL evolving in biotech, AITX evolving in automation — the latest update reflects consistent growth and rising recognition.

0 · Reply

StockHounding Oct. 19 at 1:58 AM

0 · Reply

MrTicker Oct. 17 at 9:08 PM

0 · Reply

MrTicker Oct. 17 at 9:08 PM

$ARTL BRIEF-Artelo Biosciences enters cooperation letter agreement with Daniel S. Farb - SEC filing REUTERS 4:06 PM ET 10/17/2025

0 · Reply

MrTicker Oct. 17 at 9:03 PM

0 · Reply

Paraboljoker Oct. 16 at 9:40 PM

$SUGP BIO/Hospital contract 11M🗞️ Worth Entire mcap 400k float, numers dont lie this will blow Sector hot🔥 / / $NCT $XBP $ARTL $ZBIO

0 · Reply

elmono Oct. 15 at 10:52 PM

$ARTL nobody cares about all these meetings….only 1 thing that this scam needs to do:

0 · Reply

Foamius2 Oct. 15 at 4:09 PM

$ARTL Wheres Daniel Fart? Big hat no cattle!

0 · Reply

DARKP00L Oct. 15 at 1:23 PM

$ARTL 09:18 on Oct. 15 2025 Artelo Biosciences Reports Phase 1 And 2 Data For ART26.12 And ART27.13, Highlighting Safety And Significant Weight Gain In Cancer Anorexia Trial #tradeideas

0 · Reply

MrTicker Oct. 15 at 1:19 PM

$ARTL Artelo Biosciences Reports Phase 1 And 2 Data For ART26.12 And ART27.13, Highlighting Safety And Significant Weight Gain In Cancer Anorexia Trial BENZINGA 8:18 AM ET 10/15/2025 ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo

0 · Reply

MrTicker Oct. 15 at 1:16 PM

$ARTL ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.(ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences(ARTL), is presenting expanded data from Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12, Single Ascending Dose (SAD) Study at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit, taking place October 15–16, 2025, in Boston, Massachusetts. eS).

0 · Reply

MrTicker Oct. 15 at 1:16 PM

$ARTL Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit GLOBENEWSWIRE 8:15 AM ET 10/15/2025

0 · Reply

elmono Oct. 13 at 2:29 PM

$ARTL push it down further and we go in liquidation mode on this ticker 🙏

0 · Reply

elmono Oct. 13 at 1:51 PM

$ARTL all these nanocaps suck….but this one in the bottom category 😂😂😂

0 · Reply

elmono Oct. 13 at 1:51 PM

$ARTL master scam outfit….😂😂😂

0 · Reply

StockChiefs Oct. 12 at 5:49 PM

MTEX has only 600k shares outstanding and started to make its move up Friday! Don't miss MTEX . I would rather buy before they run 200% up.. 💎 Spiked towards $15 recently . Looks like once people find MTEX we could see a squeeze up again! $LUCY $WETH.X $ERNA $ARTL will run soon

0 · Reply

ttesty Oct. 10 at 11:27 PM

$ENSC gonna get crushed by $ARTL.

1 · Reply

aim97 Oct. 10 at 4:30 PM

$ARTL bleeeding out its ass. mfer

0 · Reply

Market Cap	2.40M
Revenue (ttm)	0.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	20,100
Avg Vol	93,396
Day's Range	N/A - N/A
Shares Out	704,000.00
Stochastic %K	17%
Beta	1.41
Analysts	Hold
Price Target	$18.00